Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine
Maskatia, Z.K.; Koo, J.
Journal of Drugs in Dermatology Jdd 6(9): 941-944
2007
ISSN/ISBN: 1545-9616 PMID: 17941368 Document Number: 14537
Psoriasis rebound after efalizumab discontinuation is well-documented in the literature. We report the case of a patient who experienced psoriasis rebound 2 months after efalizumab discontinuation, despite being on more than 5 mg/kg/day of cyclosporine. This case illustrates an instance where high doses of a very efficacious antipsoriasis therapy were not sufficient to prevent efalizumab-associated rebound. In addition to describing this case, we also propose a theoretical mechanism to explain how rebound after efalizumab discontinuation comes about.
Document emailed within 1 workday
